Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Human vaccines & immunotherapeutics - 1 Jan 2015

Yousef Sara, Kovacsovics-Bankowski Magdalena, Salama Mohamed E, Bhardwaj Neelam, Steinbach Mary, Langemo Amanda, Kovacsovics Tibor, Marvin James, Binder Mascha, Panse Jens, Kröger Nicolaus, Luetkens Tim, Atanackovic Djordje

Abstract excerpt

Multiple Myeloma (MM) is a plasma cell (PC) malignancy, which despite significant therapeutic advances, is still considered incurable. This is due to the persistence of chemotherapy-resistant minimal residual disease in the patients' bone marrow (BM) after an effective induction therapy. Immunotherapies targeting surface molecules expressed on the bulk of tumor cells and the chemotherapy-resistant,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD
Share to CD56 Antigen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Immunophenotyping

Share to Monoclonal Gammopathy of Undetermined Significance

Share to Multiple Myeloma

Share to Paraproteinemias

Share to Plasma Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 26001047
DOI: 10.1080/21645515.2015.1046658
PMCID: PMC4514151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.PMID 26001047Read ↗

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.Semantic proximity Read ↗

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.Semantic proximity Read ↗

Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is LimitedSemantic proximity Read ↗

Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.Semantic proximity Read ↗

Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaSemantic proximity Read ↗

Utility of CD 54, CD 229, and CD 319 for the identification of plasma cells in patients with clonal plasma cell diseasesSemantic proximity Read ↗

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.Semantic proximity Read ↗

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.Semantic proximity Read ↗

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Semantic proximity Read ↗

[Research progress on multiple myeloma immunophenotyping and minimal residual disease detected by flow cytometry].Semantic proximity Read ↗

The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma.Semantic proximity Read ↗

Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.